吉非替尼治疗老年晚期非小细胞肺癌的疗效观察

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (12): 1410-1413.

吉非替尼治疗老年晚期非小细胞肺癌的疗效观察

李苏霞, 杨晓蕾, 陈素秀, 刘洁凡, 全世超

温州医学院附属第一医院,温州 325000,浙江

收稿日期:2013-03-26 修回日期:2013-11-05 出版日期:2013-12-26 发布日期:2014-01-04
作者简介:李苏霞,女,硕士,医师,研究方向:肺癌。Tel: 13777799062 E-mail: 1124210917@qq.com

Efficacy and safety of gefitinib treated elded-patients with advanced non-small cell lung cancer

LI Su-xia, YANG Xiao-lei, CHEN Su-xiu, LIU Jie-fan, QUAN Shi-chao

The First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, Zhejiang, China

Received:2013-03-26 Revised:2013-11-05 Online:2013-12-26 Published:2014-01-04

摘要/Abstract

摘要： 目的: 探讨吉非替尼治疗老年晚期非小细胞肺癌的有效性和安全性。方法: 对照组34例采用放疗进行治疗,观察组37例给予口服吉非替尼 250 mg/次,1次/日,比较两组的治疗总有效率、疾病控制率、不良反应发生率及治疗前后的血清糖蛋白型肺癌标志物(CA125)、粘蛋白型糖抗原(CA242)及癌胚抗原(CEA)水平的变化。结果: 观察组治疗总有效率和疾病控制率均高于对照组(χ²=3.903,χ²=4.214,P＜0.05);治疗后两组患者血清CA125、CA242及CEA水平均明显下降(P＜0.05,P＜0.01),观察组CA125和CEA低于对照组(P＜0.05);观察组不良反应发生率低于对照组,但两组差异无统计学意义(P＞0.05)。结论: 吉非替尼治疗老年中晚期非小细胞肺癌患者的临床疗效确切,耐受性好,不良反应少,值得广泛推广。

关键词: 吉非替尼, 老年, 非小细胞肺癌, CA125, 不良反应

Abstract: AIM: To investigate the effect and safety of gefitinib in elderly patients with non small cell lung cancer.METHODS: 34 elderly patients with non-small cell lung cancer treated with radiotherapy were selected as control group, and 37 patients treated with gefitinib 250mg per day were selected as observation group,then the total effective rate, disease control rates, incidence of adverse reactions and CA125,CEA,CA242 in serum of two groups were analysed and compared.RESULTS: The total effective rate and disease control rates of observation group were higher than that of control group,while the incidence of adverse reactions of two groups had no significant differences (P＞0.05) but observation group was lower. CA125,CEA,CA242 in serum were all lower than before of two groups significant differences after the treatment (P＜0.05), and observation group was lower but had no significant difference (P＞0.05).CONCLUSION: The effect and safety of gefitinib in elderly patients with non-small cell lung cancer was better,and incidence of adverse reaction was lower, that can obviously improve the quality of life for elderly patients.

Key words: Gifinitib, Elded, Non-small cell cancer, CA125, Adverse reactions

中图分类号:

R734.2

李苏霞, 杨晓蕾, 陈素秀, 刘洁凡, 全世超. 吉非替尼治疗老年晚期非小细胞肺癌的疗效观察[J]. 中国临床药理学与治疗学, 2013, 18(12): 1410-1413.

LI Su-xia, YANG Xiao-lei, CHEN Su-xiu, LIU Jie-fan, QUAN Shi-chao. Efficacy and safety of gefitinib treated elded-patients with advanced non-small cell lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(12): 1410-1413.

参考文献

[1] 孟玲楠,韩波. 吉非替尼在非小细胞肺癌放疗中增敏作用的研究进展[J]. 实用肿瘤学杂志, 2011, 25(5): 482-485.
[2] 陈东升,郁小凤. 吉非替尼治疗62例中晚期非小细胞肺癌疗效分析[J]. 中华全科医学,2010,8(4) : 433-433.
[3] 孙燕,吴一龙,李龙芸,等. 吉非替尼或多西他赛治疗一线化疗失败的非小细胞肺癌的临床分析[J]. 中华肿瘤杂志,2011,33(5):377-380.
[4] Hardy D,Cormier JN,Xing Y,et al. Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer[J]. J Thorac Oncol,2010,5(1):90-98.
[5] 顾亮,赵恬,钦光跃. 吉非替尼对比培美曲塞二线治疗晚期非小细胞肺癌的临床研究[J]. 中国临床药理学与治疗学,2012,6(5):569-573.
[6] 顾爱琴,高志强,王慧敏,等. 吉非替尼单药治疗晚期非小细胞肺癌老年患者的临床分析[J]. 上海交通大学学报:医学版,2011,31(3):305-308.
[7] 邓洁,庄亮,陈元. 吉非替尼对肺癌细胞株 H358 放疗敏感性的影响及其机制[J]. 中国肺癌杂志,2011,14(11):841-847.
[8] 王笑良,高春玲,叶性景,等. 放疗联合吉西他滨或长春瑞滨治疗Ⅲ/Ⅳ期非小细胞肺癌的近期疗效观察[J]. 现代肿瘤医学,2012,3(11): 2299-2302.
[9] 黄小珍. 吉非替尼治疗晚期非小细胞肺癌不良反应的观察及处理[J]. 现代中西医结合杂志, 2013, 8(1): 96-97.
[10] Wu CH,Fan WC,Chen YM,et al. Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients[J]. J Thorac Oncol,2010,5(3) : 376-379.
[11] 何志高,严俊,陈国涵,等. 长春瑞滨(NP)或吉西他滨(GP)联合顺铂治疗晚期非小细胞肺癌的成本效用研究[J]. 药学实践杂志,2012,11(6): 462-463.
[12] Han K,Cao W,Che J,et al. First line chemotherapy with weekly docetaxel and cisplatin in elderly patients with advanced non-small cell lung cancer:a multicenter phase II study[J]. J Thorac Oncol,2009,4(4):512-517.
[13] 王海燕,朱正学,肖燕,等. 非小细胞肺癌血清中CA125、CEA的浓度及意义[J]. 中国肺癌杂志,2008,11(1):97-100.
[14] Chiu CH,Shih YN,Tsai CM,et al. Serum tumor markers as predietors for survival in advanced non-small cell lung cancer patients treated with gefitinib[J]. Lung Cancer,2007,57(2):213-221.
[15] 刘天舟,张琳,王庆芳. 非小细胞肺癌患者血清CA153、CA242及CYFRA21-1水平测定[J].郑州大学学报:医学版,2012,47(1):113-115.
[16] 赵建强,康文菲,窦岩,等. 非小细胞肺癌患者血清CA242的含量变化及意义[J]. 山东医药,1999,39(15): 36.
[17] Zhou C,Wu YL,Chen G,et al. Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation positive non small cell lung cancer (OPTIMAL,CTONG-0802):a multicentre, open-label, randomized, phase 3study [J]. Lancet Oncol,2011,12(8):735-742.
[18] Chen G,Feng J,Zhou C,et al. Quality of life (QoL) analyses from OPTIMAL(CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer(NSCLC)[J]. Ann Oncol, 2013, 24(6): 1615-1622.